U.S. President Donald Trump on Wednesday backed away from a bipartisan deal on healthcare reached by two senators a day earlier, saying he could never support legislation "bailing out" insurance companies.
Medical technology firm Getinge reported on Wednesday quarterly core profits below expectations, sending its shares down, and said it now hoped to spin off and list its smallest division by year-end.
Proponents of a bipartisan deal struck by two U.S. senators to stabilize Obamacare sought on Wednesday to win Republican support for the measure, which would restore subsidies to health insurers that President Donald Trump has scrapped.
U.S. health insurer Anthem Inc expects $4 billion in savings starting in 2021 from its plan to end its current pharmacy contract and start managing those benefits itself, executives said on Wednesday in a conference call with investors.
Abbott Laboratories' profit and sales topped analysts' estimates on robust sales of medical devices and generic drugs, leading it to raise the high-end of its adjusted earnings forecast for the year.
* Neos Therapeutics announces settlement with Actavis on Adzenys XR-ODT patent litigation
Drug developer Alnylam Pharmaceuticals Inc said on Wednesday it would scrap its hepatitis B (HBV) drug development and instead work with Vir Biotechnology on a new treatment for the disease.
* Spectral Medical Inc - plans to commence an active search for Businskas' replacement Source text for Eikon: Further company coverage:
* Lipocine - announced FDA has scheduled bone, reproductive and urologic drugs advisory committee meeting on January 10, 2018 to discuss NDA for Tlando
* Revance completes patient enrollment in Phase 2 program for RT002 injectable in the management of plantar fasciitis